Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Lagevrio 200 mg hard capsules {equilateral_black_triangle}

Active Ingredient:
molnupiravir
Company:  
Merck Sharp & Dohme (UK) Limited See contact details
ATC code: 
J05AB18
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Patient Letter for Lagevrio (molnupiravir) – Extended Use Beyond Labelled Expiry Date.

There has been an extension to the shelf life of specific lot (batch) numbers of Lagevrio® 200 mg hard capsules, beyond the labelled expiry date by 6, 12 or 18 months (depending on the shelf life of the specific batch). Affected batches for extended use of Lagevrio® 200 mg hard capsules are annexed within this communication.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Merck Sharp & Dohme (UK) Limited
Company image
Address
120 Moorgate, London, EC2M 6UR, UK
WWW
http://www.msd-uk.com/
Telephone
+44 (0)208 154 8000 (all hours)
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)208 154 8001